Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases, is to be sold to Genfit. With this acquisition, Genfit intends to expand its product portfolio
Tags :Christian Wyss
Novaremed, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics, a China-based clinical stage neuroscience biotech company, jointly announced the signing of an exclusive collaboration and commercialization agreement for non-opioid investigational drug, NRD.E1. The
Anaveon, a Swiss clinical-stage immuno-oncology company, has agreed to a CHF 110 million Series B financing led by incoming investor Forbion, corner-stoned by founding investor Syncona, also joined by existing investor Novartis Venture Fund, as well
EnBiotix, a Boston-based biotech company focused on rare diseases, is merging with Swiss oncology and antimicrobial resistance-focused company Polyphor. A merger agreement under which Polyphor will use all of EnBiotix’s outstanding share capital in
Combioxin, a clinical phase biotechnology company based in Epalinges, Switzerland, has signed a worldwide commercial license agreement with Eagle Pharmaceuticals, a fully integrated pharmaceutical company based in Woodcliff Lake, NY, USA. Under the terms of
Novartis has signed a collaboration agreement and option to acquire Cellerys, a Zurich-based start-up that is researching a therapy to combat multiple sclerosis (MS). This therapy has the potential to delay the progression of the
Vischer acted as legal counsel for Haya Therapeutics, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), on the closing of its CHF 18 million seed round. The financing was led
Vischer advised the sellers of Mestex AG on all legal issues related to the sale of their shares and stock options to the pharmaceutical company Grünenthal, a global operator in pain management and related
The team consists of Christian Wyss (Partner, Corporate / M&A), Sebastian Flückiger (Associate, Corporate / M&A), and Adrian Briner (Associate, Tax).
The team, led by partner Adrian Dörig (Corporate Finance - pictured) included Peter Kühn (Counsel, Corporate / M&A), Michel Stübi and Florian Angstmann (Associates, Corporate / M&A), Aleksandra Simic (Junior Associate, Corporate /
